Patents by Inventor Akira Miyakoshi
Akira Miyakoshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10865247Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: GrantFiled: February 20, 2020Date of Patent: December 15, 2020Assignees: GeneFrontier Corporation, National University Corporation Chiba UniversityInventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
-
Publication number: 20200199235Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: February 20, 2020Publication date: June 25, 2020Applicants: GeneFrontier Corporation, National University Corporation Chiba UniversityInventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
-
Patent number: 10640573Abstract: The present invention provides an antibody that specifically binds to human aggrecanase, and inhibits enzymatic activity of the human aggrecanase. In one embodiment, aggrecanase is ADAMTS4. In one embodiment, the antibody recognizes a particular epitope in human ADAMTS4, and inhibits not only aggrecanase activity of human ADAMTS4 but also aggrecanase activity of human ADAMTS5. In addition, the present invention also provides use of said antibody in the prophylaxis or treatment of the progression of arthritis.Type: GrantFiled: October 5, 2018Date of Patent: May 5, 2020Assignees: GeneFrontier Corporation, Keio UniversityInventors: Akira Miyakoshi, Mikiko Nakamura, Kanehisa Kojoh, Satsuki Mochizuki, Yasunori Okada
-
Patent number: 10556967Abstract: The present invention provides an antibody that specifically binds to human ADAM28, inhibits enzyme activity of human ADAM28, and has an activity to suppress metastasis of a cancer cell that expresses human ADAM28. The antibody of the present invention can be a human antibody.Type: GrantFiled: November 16, 2017Date of Patent: February 11, 2020Assignees: GENEFRONTIER CORPORATION, KEIO UNIVERSITYInventors: Akira Miyakoshi, Rena Matsumoto, Shizue Katoh, Yuki Hayami, Satsuki Mochizuki, Masayuki Shimoda, Yasunori Okada
-
Publication number: 20190233521Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: October 5, 2018Publication date: August 1, 2019Applicants: GeneFrontier Corporation, National University Corporation Chiba UniversityInventors: Kanehisa KOJOH, Akira MIYAKOSHI, Shizue KATOH, Kumiko TSUIHIJI, Yuki HAYAMI, Mikiko NAKAMURA, Toshinori NAKAYAMA, Chiaki IWAMURA
-
Publication number: 20190233541Abstract: The present invention provides an antibody that specifically binds to human aggrecanase, and inhibits enzymatic activity of the human aggrecanase. In one embodiment, aggrecanase is ADAMTS4. In one embodiment, the antibody recognizes a particular epitope in human ADAMTS4, and inhibits not only aggrecanase activity of human ADAMTS4 but also aggrecanase activity of human ADAMTS5. In addition, the present invention also provides use of said antibody in the prophylaxis or treatment of the progression of arthritis.Type: ApplicationFiled: October 5, 2018Publication date: August 1, 2019Applicants: GeneFrontier Corporation, Keio UniversityInventors: Akira MIYAKOSHI, Mikiko NAKAMURA, Kanehisa KOJOH, Satsuki MOCHIZUKI, Yasunori OKADA
-
Patent number: 10329358Abstract: The present invention provides an antibody having an activity to specifically bind to human membrane-anchored form ADAM28 at an epitope in a region of the 524th-659th amino acids in the amino acid sequence shown in SEQ ID NO: 2. In addition, the present invention provides a drug delivery vehicle for delivering a drug to a cell or tissue that expresses human membrane-anchored form ADAM28, which contains the antibody.Type: GrantFiled: March 4, 2016Date of Patent: June 25, 2019Assignees: GeneFrontier Corporation, KEIO UNIVERSITYInventors: Akira Miyakoshi, Kanehisa Kojoh, Satsuki Mochizuki, Masayuki Shimoda, Yasunori Okada
-
Publication number: 20180155448Abstract: The present invention provides an antibody that specifically binds to human ADAM28, inhibits enzyme activity of human ADAM28, and has an activity to suppress metastasis of a cancer cell that expresses human ADAM28. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: November 16, 2017Publication date: June 7, 2018Applicants: GENEFRONTIER CORPORATION, KEIO UNIVERSITYInventors: Akira MIYAKOSHI, Rena MATSUMOTO, Shizue KATOH, Yuki HAYAMI, Satsuki MOCHIZUKI, Masayuki SHIMODA, Yasunori OKADA
-
Publication number: 20180044435Abstract: The present invention provides an antibody having an activity to specifically bind to human membrane-anchored form ADAM28 at an epitope in a region of the 524th-659th amino acids in the amino acid sequence shown in SEQ ID NO: 2. In addition, the present invention provides a drug delivery vehicle for delivering a drug to a cell or tissue that expresses human membrane-anchored form ADAM28, which contains the antibody.Type: ApplicationFiled: March 4, 2016Publication date: February 15, 2018Applicants: GeneFrontier Corporation, KEIO UNIVERSITYInventors: Akira MIYAKOSHI, Kanehisa KOJOH, Satsuki MOCHIZUKI, Masayuki SHIMODA, Yasunori OKADA
-
Patent number: 9845364Abstract: The present invention provides an antibody that specifically binds to human ADAM28, inhibits enzyme activity of human ADAM28, and has an activity to suppress metastasis of a cancer cell that expresses human ADAM28. The antibody of the present invention can be a human antibody.Type: GrantFiled: October 1, 2013Date of Patent: December 19, 2017Assignees: GeneFrontier Corporation, Keio UniversityInventors: Akira Miyakoshi, Rena Matsumoto, Shizue Katoh, Yuki Hayami, Satsuki Mochizuki, Masayuki Shimoda, Yasunori Okada
-
Patent number: 9493523Abstract: Provided is an antigen-binding protein prepared merely by a method of in vitro selection using the RNF8-FHA domain, which has no intramolecular disulfide bond and functions in cells as it is. One to four loops extending from the FHA domain are randomized, and a recognition site for a target molecule is artificially created on the FHA domain surface to construct an RNF8-FHA domain library. Using the library, an antigen-binding protein is efficiently selected in vitro.Type: GrantFiled: May 6, 2011Date of Patent: November 15, 2016Assignee: GeneFrontier CorporationInventors: Kanehisa Kojoh, Shizue Katoh, Akira Miyakoshi, Mikiko Nakamura
-
Publication number: 20160304622Abstract: The present invention provides an antibody that specifically binds to human aggrecanase, and inhibits enzymatic activity of the human aggrecanase. In one embodiment, aggrecanase is ADAMTS4. In one embodiment, the antibody recognizes a particular epitope in human ADAMTS4, and inhibits not only aggrecanase activity of human ADAMTS4 but also aggrecanase activity of human ADAMTS5. In addition, the present invention also provides use of said antibody in the prophylaxis or treatment of the progression of arthritis.Type: ApplicationFiled: October 14, 2014Publication date: October 20, 2016Applicants: GeneFrontier Corporation, Keio UniversityInventors: Akira MIYAKOSHI, Mikiko NAKAMURA, Kanehisa KOJOH, Satsuki MOCHIZUKI, Yasunori OKADA
-
Publication number: 20150274840Abstract: The present invention provides an antibody that specifically binds to human ADAM28, inhibits enzyme activity of human ADAM28, and has an activity to suppress metastasis of a cancer cell that expresses human ADAM28. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: October 1, 2013Publication date: October 1, 2015Inventors: Akira Miyakoshi, Rena Matsumoto, Shizue Katoh, Yuki Hayami, Satsuki Mochizuki, Masayuki Shimoda, Yasunori Okada
-
Patent number: 9133452Abstract: The present invention provides a method of producing a maturated oligonucleotide library, including a step of obtaining a terminal-modified product of a maturation target oligonucleotide library, including adding a tag sequence to the 5? terminus of the maturation target oligonucleotide library and an arrest sequence, which stalls translation elongation on a ribosome, to the 3? terminus of the maturation target oligonucleotide library, a step of transcribing the terminal-modified sequence product to give a transcript, and a step of in vitro translation for translating the transcript in vitro, wherein the maturation target oligonucleotide library is a random oligonucleotide library.Type: GrantFiled: June 23, 2011Date of Patent: September 15, 2015Assignees: The University of Tokyo, GeneFrontier CorporationInventors: Takuya Ueda, Takashi Kanamori, Kanehisa Kojoh, Shizue Katoh, Akira Miyakoshi
-
Publication number: 20150118237Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: April 23, 2013Publication date: April 30, 2015Inventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
-
Publication number: 20130143299Abstract: Provided is an antigen-binding protein prepared merely by a method of in vitro selection using the RNF8-FHA domain, which has no intramolecular disulfide bond and functions in cells as it is. One to four loops extending from the FHA domain are randomized, and a recognition site for a target molecule is artificially created on the FHA domain surface to construct an RNF8-FHA domain library. Using the library, an antigen-binding protein is efficiently selected in vitro.Type: ApplicationFiled: May 6, 2011Publication date: June 6, 2013Applicant: GENEFRONTIER CORPORATIONInventors: Kanehisa Kojoh, Shizue Katoh, Akira Miyakoshi, Mikiko Nakamura
-
Publication number: 20130143773Abstract: The present invention provides a method of producing a maturated oligonucleotide library, including a step of obtaining a terminal-modified product of a maturation target oligonucleotide library, including adding a tag sequence to the 5? terminus of the maturation target oligonucleotide library and an arrest sequence, which stalls translation elongation on a ribosome, to the 3? terminus of the maturation target oligonucleotide library, a step of transcribing the terminal-modified sequence product to give a transcript, and a step of in vitro translation for translating the transcript in vitro, wherein the maturation target oligonucleotide library is a random oligonucleotide library.Type: ApplicationFiled: June 23, 2011Publication date: June 6, 2013Applicants: GENEFRONTIER CORPORATION, THE UNIVERSITY OF TOKYOInventors: Takuya Ueda, Takashi Kanamori, Kanehisa Kojoh, Shizue Katoh, Akira Miyakoshi
-
Patent number: 6852646Abstract: A method for forming a dielectric film in a PDP includes the steps of: reducing the ambient pressure of an insulating film including a dielectric material before the ambient temperature reaches the reaction temperature of the dielectric material; introducing heated gas to increase the ambient pressure up to the atmospheric pressure while maintaining the ambient temperature at the reaction temperature; and lowering the ambient temperature down to the solidifying temperature of the insulating film while maintaining the atmospheric ambient pressure.Type: GrantFiled: July 9, 2002Date of Patent: February 8, 2005Assignee: NEC CorporationInventors: Toshihiro Yoshioka, Akira Miyakoshi
-
Patent number: 6734626Abstract: In order to improve the light emitting efficiency of a surface-discharge type color PDP, a sustaining electrode is divided into a plurality of electrodes formed in respective different layers. Lower electrodes 121 and upper electrodes 122 in different layers are formed as electrode pairs, an upper dielectric layer 14 is formed on the upper electrodes 122 in an upper layer to make a dielectric layer on the surface-discharge electrode pair thin to thereby maintain the discharge sustaining voltage low and obtain high light emitting efficiency.Type: GrantFiled: July 24, 2001Date of Patent: May 11, 2004Assignee: NEC CorporationInventors: Toshihiro Yoshioka, Akira Miyakoshi
-
Publication number: 20030013244Abstract: A method for forming a dielectric film in a PDP includes the steps of: reducing the ambient pressure of an insulating film including a dielectric material before the ambient temperature reaches the reaction temperature of the dielectric material; introducing heated gas to increase the ambient pressure up to the atmospheric pressure while maintaining the ambient temperature at the reaction temperature; and lowering the ambient temperature down to the solidifying temperature of the insulating film while maintaining the atmospheric ambient pressure.Type: ApplicationFiled: July 9, 2002Publication date: January 16, 2003Applicant: NEC CORPORATIONInventors: Toshihiro Yoshioka, Akira Miyakoshi